Medical Device Vulnerability Management: A Practical Guide

Medical device vulnerability management is the coordinated process for identifying, evaluating, remediating, communicating, and monitoring cybersecurity weaknesses throughout a device’s supported lifecycle. It connects technical security work with patient safety, quality management, regulatory obligations, and customer communication.

For connected medical devices and Software as a Medical Device (SaMD), vulnerability management cannot begin after commercial release. Manufacturers need the architecture, software inventory, update capability, responsibilities, and decision criteria required to respond when a vulnerability is discovered. In this guide, we outline a practical, traceable process designed to support both regulatory readiness and effective postmarket response.

Why Does Medical Device Vulnerability Management Matter?

A vulnerability may affect more than confidentiality. Exploitation could alter clinical data, interrupt therapy, make an essential function unavailable, or provide unauthorized access to connected systems. The response must therefore consider technical exploitability and potential effects on medical device safety and effectiveness.

FDA’s February 2026 premarket cybersecurity guidance uses a total product lifecycle approach. For qualifying premarket submissions involving cyber devices, Section 524B requires sponsors to provide a plan for monitoring, identifying and addressing postmarket cybersecurity vulnerabilities and exploits, including coordinated vulnerability disclosure procedures. Sponsors must also establish processes for providing cybersecurity updates and patches and submit a software bill of materials (SBOM).

FDA-recognized AAMI TIR97:2019 offers complementary guidance for postmarket security risk management, including monitoring, coordinated disclosure, patching, stakeholder communication, and device retirement.

How Is Vulnerability Management Different From Risk Assessment?

A cybersecurity risk assessment evaluates threats, vulnerabilities, hazardous situations, controls, and residual risk for the device. Vulnerability management is the ongoing operational process that handles weaknesses as products, components, attack methods, and field information change.

The two activities should remain connected. A newly identified vulnerability may change an existing risk conclusion, expose a new attack path, or require additional testing and controls. QCC’s guide to medical device cybersecurity risk assessment provides additional discussion of the broader risk framework.

A Practical Vulnerability Management Process

An effective workflow should define ownership, escalation criteria, expected timelines, required records, and communication authority before an urgent issue arises.

1. Maintain Device and Software Visibility

Keep an accurate inventory of supported products, versions, configurations, interfaces, cloud services, and third-party components. A current Software Bill of Materials (SBOM) helps teams determine whether a disclosed component vulnerability affects a particular device build.

The inventory should also identify product owners, support status, end-of-support dates, deployed populations where available, and approved communication channels. An SBOM without version and configuration control may create false matches or miss affected products.

2. Monitor and Receive Vulnerability Information

Monitor appropriate sources such as supplier notices, security researchers, vulnerability databases, information-sharing organizations, internal testing, customer reports, and CISA’s Known Exploited Vulnerabilities Catalog. Establish a public vulnerability-disclosure policy with a monitored reporting channel and clear instructions for researchers.

Each report should receive an identifier, owner, date, status, and acknowledgment. Intake procedures should protect sensitive details while allowing engineering, security, quality, regulatory, and clinical teams to collaborate.

3. Validate and Determine Scope

Confirm whether the weakness is reproducible and which device versions, components, configurations, and environments are affected. A published Common Vulnerabilities and Exposures identifier or high Common Vulnerability Scoring System score does not automatically establish device impact.

The affected function may be unreachable, disabled, modified, or protected by compensating controls. Conversely, a moderate technical score may still matter if exploitation can affect an essential clinical function. Document applicability conclusions with objective evidence. A Vulnerability Exploitability eXchange statement may help communicate component status when appropriate.

4. Evaluate Safety and Security Risk

Assess attack feasibility, required access, privileges, known exploitation, detectability, device exposure, and available controls. Then connect the cybersecurity event to potential device effects, hazardous situations, and patient harm.

Do not rely on CVSS alone. Prioritization should combine security characteristics with clinical context and the organization’s established risk criteria. Update the security and safety risk files when new information changes prior assumptions.

5. Remediate or Mitigate the Vulnerability

Select a response appropriate to the risk and affected population. Options may include a software update, configuration change, compensating control, monitoring rule, customer instruction, component replacement, or product retirement.

Updates should be developed and tested under controlled processes. Verify authenticity, integrity, installation behavior, rollback or recovery where applicable, and the absence of unacceptable new risks. Define deployment priorities and timelines rather than treating every finding identically.

6. Coordinate Disclosure and Communication

Communication may involve researchers, component suppliers, health care delivery organizations, patients, regulators, and information-sharing bodies. Coordinate timing so that users receive useful mitigation information without unnecessary exposure of exploitable details.

Messages should identify affected products and versions, describe the risk in understandable terms, provide mitigations or update instructions, and explain how users can obtain support. Regulatory reporting and submission obligations should be evaluated for the specific issue and jurisdiction.

7. Verify Closure and Capture Lessons

Confirm that the remediation works, track deployment where feasible, and monitor for exploitation, installation problems, or new variants. Closure records should link the original report to the assessment, decisions, testing, communications, and approvals.

Use the outcome to improve threat models, security requirements, supplier controls, testing, SBOM governance, and future product designs. Vulnerability management should create feedback into the quality management system rather than operate as a separate security queue.

Common Vulnerability Management Gaps

Frequent weaknesses include:

• Incomplete inventories or outdated SBOMs
• Unclear ownership between security, engineering, quality, and regulatory teams
• Assessments based only on CVSS scores
• Undocumented “not affected” conclusions
• Patch plans without verification, recovery, or deployment evidence
• Inconsistent safety and security risk records
• No coordinated vulnerability disclosure process
• Unsupported products without a defined retirement or customer-transition plan

A tabletop exercise can test whether the organization can receive a report, identify affected products, make a documented risk decision, develop a response, and communicate within its target timeline.

How Quality Commercial Consultants Can Help

At Quality Commercial Consultants, we help software-enabled medical device and SaMD companies prepare clear, FDA-ready cybersecurity compliance documentation. Our support may include vulnerability-management plans, SBOM and traceability reviews, safety and security risk alignment, postmarket documentation, submission-readiness assessments, and responses to FDA Additional Information requests.

Contact Us Today

Contact our QCC team to discuss your device, vulnerability-management process, submission timeline, and current cybersecurity documentation. We can help you identify gaps, prioritize next steps, and prepare documentation that supports FDA expectations.